Image

Preventing Iatrogenic Dependence Linked to Hospitalisation in Elderly Patients Hospitalised in Acute Geriatrics

Preventing Iatrogenic Dependence Linked to Hospitalisation in Elderly Patients Hospitalised in Acute Geriatrics

Recruiting
75 years and older
All
Phase N/A

Powered by AI

Overview

Iatrogenic dependence linked to hospitalisation DILH is very frequent, severe but avoidable in 80% of cases. Extensive research has identified 6 main causes of DILH in the elderly, which interact and have common risk factors: immobilisation, falls, undernutrition, de novo urinary incontinence, confusion and drug side-effects.

Our main hypothesis is that promoting access to, knowledge of and implementation of good practice recommendations by healthcare staff (medical and paramedical) concerning DILH in the elderly, based on graded interventions and targeting the 6 main causes of DILH, via the TAKE CARE intervention could reduce the incidence of DILH in the population of patients aged 75 or over hospitalised in acute geriatric units excluding post-operative and post-resuscitation, in the context of unscheduled hospitalizations.

A Multicenter, randomized, cluster trial evaluating the effect of the TAKE CARE intervention compared with usual care in patients will be conducted across 11 acute geriatric services in France. A total of 2200 patients will be needed for a total period of 6 months with a 6 months followup prior inclusion. Data will be collected directly from the patients' medical records and entered by an investigator or a clinical study technician in an electronic CRF (CleanWeb) managed by the URC PSL.

The trial will also include a qualitative component to assess, among other things, the implementation aspects of this complex intervention (individual interviews, focus group). A medico-economic component with a cost-utility analysis to assess the incremental cost-utility ratio, and a hospital microcosting study to assess the costs associated with the TAKE CARE intervention.

The impact of the TAKE CARE intervention will be studied using a "win-ratio" approach based on a hierarchical composite criterion that takes into account vital status at D7 and the change in ADL score between D15 before admission and D7. The difference in ADL score between D-15 and D7 will be compared between the 2 randomisation groups using a mixed linear model with the randomisation arm as a fixed effect and a random effect on the cluster. A win-ratio significantly greater than 1 will allow us to conclude that the TAKE CARE intervention is effective.

Description

Hospitalization for an acute illness in older individuals is connected to a decline in functionality, referred to as iatrogenic dependence linked to hospitalization (DILH). This is characterized by the inability to perform essential daily activities necessary for independent living. The literature has identified six primary causes of DILH in the elderly, which interact and share common risk factors. These causes include immobilization, falls, undernutrition, de novo urinary incontinence, confusion, and drug side effects. DILH is a prevalent issue, affecting approximately 40% of elderly patients admitted to the hospital. However, it is important to note that 80% of these cases can be prevented with appropriate measures.

Our primary hypothesis revolves around the idea that by promoting access to, knowledge of, and implementation of best practice recommendations among healthcare staff (both medical and paramedical) regarding DILH in the elderly, we can effectively reduce the incidence of DILH in the population of patients aged 75 or over who are hospitalized in acute geriatric units (excluding post-operative and post-resuscitation cases) during unscheduled hospitalizations. This will be achieved through the implementation of the TAKE CARE intervention, which is a multifaceted organizational intervention designed to facilitate the adoption of all current recommendations for combating DILH in the elderly, utilizing innovative equipment such as portable and connected treadmills, installation of lighting with motion detectors in hospital room and use of the SYNAPSEMed application .

A randomized, cluster trial will be conducted across 11 acute geriatric services in France to evaluate the impact of the TAKE CARE intervention compared to usual care in patients. The trial will span over a period of 6 months, during which a total of 2200 patients will be included. Half of the patients (n=1,100) will be admitted to the 11 wings of the geriatric ward in the INTERVENTION arm, while the other half (n=1,100) will be assigned to the 11 wings in the control arm. Following the inclusion period, the patients will be followup for a period of 6 months. Demographic and clinical data will be collected from the patients' medical records and entered into an electronic CRF (CleanWeb) by either an investigator or a clinical study technician. The URC PSL will manage the CRF through the eTAKE-CARE® application, as well as the SynapseMed® application. Data management and statistical analysis will be conducted by the PSL-CFX URC, using either the statistical software R version 3.6.3 or later (R Foundation for Statistical Computing, Vienna, Austria, https://www.R-project.org/) or SAS (SAS Institute Inc., Cary, NC, USA).

The trial will also include a qualitative component to assess, among other things, the implementation aspects of this complex intervention (individual interviews, focus group). A medico-economic component with a cost-utility analysis to assess the incremental cost-utility ratio, and a hospital microcosting study to assess the costs associated with the TAKE CARE intervention. QALYs (quality of life) will be assessed using the EQ5D-3L scale, which is robust in the geriatric population. Two aspects will be taken into account when estimating the cost utility, one will be the costs attributable to the purchase and immobilisation of the equipment necessary for the implementation of the intervention, and on the other hand, the costs associated with operating this equipment in relation to patient care.

The effectiveness of the TAKE CARE intervention will be examined through the utilization of a "win-ratio" method, which employs a hierarchical composite criterion. This criterion considers the vital status at D7 and the change in ADL score between D15 prior to admission and D7. By comparing the difference in ADL score between D-15 and D7 in the two randomization groups using a mixed linear model, with the randomization arm as a fixed effect and a random effect on the cluster. A win-ratio significantly greater than 1 will allow us to conclude that the TAKE CARE intervention is effective.

Eligibility

Inclusion Criteria:

  • Age ≥ 75 ans
  • Unscheduled hospitalisation in one of the participating departments for an acute pathology, excluding post-operative care

Exclusion Criteria:

  • Patients with a usual ADL score (assessed 15 days before hospitalisation) of 0
  • Stay > 72 hours in another facility before admission to UGA
  • Opposition to participation in the study (trusted support person / guardian - curator)
  • Not affiliated to a social security scheme (beneficiary or beneficiary entitled)
  • Patient under AME

Study details
    An Acute Pathology

NCT06449053

Assistance Publique - Hôpitaux de Paris

15 October 2025

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.